Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Gastroenterology

Journal Scan / Consensus and Guidelines · January 01, 2025

Resmetirom Therapy for the Management of Patients With MASLD: Updates to the AASLD Practice Guidance

Hepatology (Baltimore, Md.)

 

Additional Info

Hepatology (Baltimore, Md.)
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Hepatology 2025 Jan 01;81(1)312-320, VL Chen, TR Morgan, Y Rotman, HM Patton, K Cusi, F Kanwal, WR Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading